MyDirectives and Delaware Health Information Network Partner to Build Statewide Advance Care Planning Ecosystem

MyDirectives and the Delaware Health Information Network announced a five-year partnership to build and support a statewide advance care planning ecosystem. The initiative aims to make advance directives and portable medical orders securely available through DHIN’s statewide connectivity and MyDirectives’ national infrastructure.

Analysis

The announcement is strategically useful validation for digital advance-care-planning workflows, but it does not establish a material revenue opportunity: contract value, funding source, deployment scope, adoption targets, and payment terms are undisclosed. A statewide footprint is a bounded proof point, not evidence of national-scale demand. The key economic test is whether directives are reliably surfaced in clinical workflows and acted on—not simply stored or made technically accessible. If usage remains low, the partnership may deliver limited commercial value; if it demonstrates repeatable integration and clinician adoption, it could strengthen MyDirectives’ position in future health-system or state procurements. Potential beneficiaries include ACP workflow vendors and interoperability providers; incumbent EHR platforms could also capture value if they control the point-of-care interface. Those are conditional competitive effects, not confirmed awards or displacement. Near term, the release is unlikely to support a meaningful public-equity trade given the absence of identified listed securities or disclosed financial terms. Over 1–3 months, seek implementation milestones and named participating organizations. Over 6–18 months, adoption, renewal, and replication outside Delaware would be the stronger evidence of a scalable business. The thesis weakens if rollout slips, clinician use is minimal, or no further deployments emerge.

Key Decisions for Investors

• No immediate trade: the announcement lacks disclosed economics and the supplied data identifies no relevant listed company or ticker.
• Treat this as a watch item for digital-health and interoperability diligence; verify contract value, who funds the initiative, implementation costs, participating care organizations, and whether MyDirectives receives recurring fees.
• Track deployment milestones and measures of workflow use—not just records made available. Broader adoption or replication beyond Delaware would improve the case for a scalable commercial opportunity.
• Falsification signals: delayed rollout, limited clinician utilization, no follow-on deployments over the next 6–18 months, or evidence that the initiative is primarily a subsidized/noncommercial program.